









Markets
/
Stocks
/
nasdaq-crbp
/

Corbus Pharmaceuticals Holdings Inc

CRBP

9.240USD

+0.930+11.19%

Close 03/26, 16:00（ET）Quotes delayed by 15 min

7.78MMarket Cap

LossP/E TTM



Corbus Pharmaceuticals Holdings Inc

9.240

+0.930+11.19%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Corbus Pharmaceuticals Holdings Inc

Currency: USD Updated: 2026-03-26

Key Insights

Corbus Pharmaceuticals Holdings Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 74 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 42.11.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Corbus Pharmaceuticals Holdings Inc's Score

Industry at a Glance

Industry Ranking

74 / 391

Overall Ranking

176 / 4546

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Corbus Pharmaceuticals Holdings Inc Highlights

StrengthsRisks

Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Fairly Valued

The company’s latest PE is -1.57, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 9.91M shares, increasing 9.02% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 354.30K shares of this stock.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

42.111

Target Price

+414.81%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-26

The current financial score of Corbus Pharmaceuticals Holdings Inc is 6.67, ranking 219 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

6.67

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.53

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Corbus Pharmaceuticals Holdings Inc's Company Valuation

Currency: USD Updated: 2026-03-26

The current valuation score of Corbus Pharmaceuticals Holdings Inc is 6.96, ranking 193 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.57, which is -99.55% below the recent high of -0.01 and -579.63% above the recent low of -10.65.

Score

Industry at a Glance

Previous score

6.96

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 74/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-26

The current earnings forecast score of Corbus Pharmaceuticals Holdings Inc is 8.80, ranking 51 out of 391 in the Biotechnology & Medical Research industry. The average price target is 39.00, with a high of 53.00 and a low of 28.00.

Score

Industry at a Glance

Previous score

8.80

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

42.111

Target Price

+414.81%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Corbus Pharmaceuticals Holdings Inc

CRBP

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-26

The current price momentum score of Corbus Pharmaceuticals Holdings Inc is 7.52, ranking 67 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 10.58 and the support level at 7.79, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.95

Change

0.57

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.167

Neutral

RSI(14)

55.908

Neutral

STOCH(KDJ)(9,3,3)

33.705

Buy

ATR(14)

0.765

Low Volatility

CCI(14)

-38.556

Neutral

Williams %R

51.797

Neutral

TRIX(12,20)

0.383

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

8.552

Buy

MA10

8.930

Buy

MA20

8.924

Buy

MA50

8.442

Buy

MA100

9.165

Buy

MA200

10.010

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-26

The current institutional shareholding score of Corbus Pharmaceuticals Holdings Inc is 7.00, ranking 85 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 80.52%, representing a quarter-over-quarter decrease of 29.12%. The largest institutional shareholder is The Vanguard, holding a total of 859.41K shares, representing 4.85% of shares outstanding, with 11.80% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Cormorant Asset Management, LP

2.34M

-1.26%

OrbiMed Advisors, LLC

1.17M

abrdn Inc.

188.23K

+160.61%

Octagon Capital Advisors LP

1.11M

The Vanguard Group, Inc.

Star Investors

612.03K

+2.09%

Citadel Advisors LLC

980.61K

Prosight Capital

343.40K

-40.78%

Armistice Capital LLC

192.00K

Renaissance Technologies LLC

Star Investors

107.20K

-30.18%

Risk Assessment

Currency: USD Updated: 2026-03-26

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Corbus Pharmaceuticals Holdings Inc is 3.03, ranking 172 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 2.87. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Corbus Pharmaceuticals Holdings Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.